finasteride

Summary

Summary: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.

Top Publications

  1. Lee C, Ha U, Yim S, Lee H, Sohn D, Han C, et al. Does finasteride have a preventive effect on chronic bacterial prostatitis? Pilot study using an animal model. Urol Int. 2011;86:204-9 pubmed publisher
    To evaluate the preventive effect of finasteride on chronic bacterial prostatitis (CBP), Wistar rats were divided into four groups: control, ciprofloxacin, finasteride, and ciprofloxacin/finasteride.
  2. Fwu C, Eggers P, Kaplan S, Kirkali Z, Lee J, Kusek J. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. J Urol. 2013;190:187-93 pubmed publisher
    We examined the effects of doxazosin, finasteride and combination therapy among men with benign prostatic hyperplasia on quality of life assessed with MOS-SF-36 (Medical Outcomes Study Short-Form 36) and 2 disease specific instruments (..
  3. Garcia P, Barbieri M, Perobelli J, Consonni S, Mesquita S, Kempinas W, et al. Morphometric-stereological and functional epididymal alterations and a decrease in fertility in rats treated with finasteride and after a 30-day post-treatment recovery period. Fertil Steril. 2012;97:1444-51 pubmed publisher
    ..changes in the epididymal caput, sperm quality, and fertility parameters in rats treated with finasteride and after a 30-day post-treatment recovery period. Experimental study in a research laboratory...
  4. Hong J, Chiu H, Chan J, Chen R, Lin S. A woman with iatrogenic androgenetic alopecia responding to finasteride. Br J Dermatol. 2007;156:754-5 pubmed
  5. Kaplan S, Lee J, Meehan A, Kusek J. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol. 2011;185:1369-73 pubmed publisher
    This post hoc analysis of the Medical Therapy of Prostatic Symptoms trial examined the effect of finasteride alone compared to placebo on the clinical progression of benign prostatic hyperplasia in men with a baseline prostate volume ..
  6. Bass R, Perry B, Langenstroer P, Thrasher J, Dennis K, Tawfik O, et al. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. J Urol. 2009;181:615-9; discussion 619-20 pubmed publisher
    We explored the molecular correlates of the effect of finasteride on prostate tissue in patients undergoing radical prostatectomy. Patients undergoing radical prostatectomy for localized prostate cancer were eligible for study...
  7. Thompson I, Tangen C, Goodman P, Lucia M, Parnes H, Lippman S, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol. 2007;177:1749-52 pubmed
    ..We previously presented data from the Prostate Cancer Prevention Trial indicating that finasteride improves the performance characteristics of prostate specific antigen for cancer detection...
  8. Reed S, Scales C, Stewart S, Sun J, Moul J, Schulman K, et al. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. J Urol. 2011;185:841-7 pubmed publisher
    ..and quality adjusted survival across risk groups for patients receiving or not receiving chemoprevention with finasteride. The model uses data from national cancer registries, online sources and the medical literature...
  9. Chhipa R, Halim D, Cheng J, Zhang H, Mohler J, Ip C, et al. The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific. Prostate. 2013;73:1483-94 pubmed publisher
    b>Finasteride and dutasteride were developed originally as 5?-reductase inhibitors to block the conversion of testosterone to dihydrotestosterone (DHT)...

More Information

Publications62

  1. Golbano J, Lóppez Aparicio P, Recio M, Pérez Albarsanz M. Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. Int J Oncol. 2008;32:919-24 pubmed
    We investigated the effects of finasteride, a 5alpha-reductase inhibitor, on cell death machinery through the induction of apoptosis in an in vitro model for prostate cancer...
  2. Kristal A, Schenk J, Song Y, Arnold K, Neuhouser M, Goodman P, et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;168:1416-24 pubmed publisher
    ..Genetic or environmental factors that affect the activity of 5-alpha-reductase may be important in the development of symptomatic BPH. ..
  3. Dörsam J, Altwein J. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. Prostate Cancer Prostatic Dis. 2009;12:130-6 pubmed publisher
    ..The 5ARIs Finasteride and Dutasteride, which specifically inhibit the production of dihydrotestosterone by acting as competitive ..
  4. Thompson I, Tangen C, Parnes H, Lippman S, Coltman C. Does the level of prostate cancer risk affect cancer prevention with finasteride?. Urology. 2008;71:854-7 pubmed publisher
    b>Finasteride reduced the risk of prostate cancer by 24.8% in the Prostate Cancer Prevention Trial (PCPT). Whether this represents treatment or prevention and who is most likely to benefit are unknown...
  5. Gong Z, Kristal A, Schenk J, Tangen C, Goodman P, Thompson I. Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer. 2009;115:3661-9 pubmed publisher
    ..In the placebo arm, there was no association of drinking with risk of low-grade cancer. In the finasteride arm, drinking > or =50 g of alcohol daily was associated with an increased risk of low-grade disease (RR, 1...
  6. Duskova M, Hill M, Starka L. Changes of metabolic profile in men treated for androgenetic alopecia with 1 mg finasteride. Endocr Regul. 2010;44:3-8 pubmed
    ..b>Finasteride, used for treatment of androgenetic alopecia at a dose of 1mg/day, is an effective inhibitor of type II 5alpha-..
  7. Opoku Acheampong A, Nelsen M, Unis D, Lindshield B. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice. PLoS ONE. 2012;7:e29068 pubmed publisher
    ..Previously, finasteride (5?R2 inhibitor) treatment begun 3 weeks post-tumor implantation had no effect on Dunning R3327-H rat prostate ..
  8. Ramaker M, Ford M, Fretwell A, Finn D. Alteration of ethanol drinking in mice via modulation of the GABA(A) receptor with ganaxolone, finasteride, and gaboxadol. Alcohol Clin Exp Res. 2011;35:1994-2007 pubmed publisher
    ..with the synthetic GABAergic neurosteroid ganaxolone (GAN), with an inhibitor of neurosteroid synthesis (finasteride [FIN]), or a GABA(A) receptor agonist with some selectivity at extrasynaptic receptors (gaboxadol HCL [THIP])...
  9. Roth M, Dudley R, Hull L, Leung A, Christenson P, Wang C, et al. Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5?-reductase by finasteride. Int J Androl. 2011;34:541-7 pubmed publisher
    ..We hypothesized that finasteride would increase serum testosterone and lower DHT during treatment with oral TU...
  10. Chiba K, Yamaguchi K, Li F, Ando M, Fujisawa M. Finasteride-associated male infertility. Fertil Steril. 2011;95:1786.e9-11 pubmed publisher
    To describe a male patient with finasteride-associated infertility. Case report. Tertiary-care clinic for male infertility. A patient with azoospermia who had been taking finasteride (1-mg dose) for 1 year for androgenic alopecia...
  11. Verdi J, Ahmadiani A. Finasteride, a 5alpha-reductase inhibitor, potentiates antinociceptive effects of morphine, prevents the development of morphine tolerance and attenuates abstinence behavior in the rat. Horm Behav. 2007;51:605-10 pubmed
    ..In the present study, we investigated inhibition of 5alpha-reductase enzyme on morphine effects using finasteride. To determine whether the 5alpha-reductase enzyme interact with morphine analgesia, finasteride (5 mg/kg, i.p...
  12. Thevis M, Geyer H, Mareck U, Flenker U, Schanzer W. Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite. Ther Drug Monit. 2007;29:236-47 pubmed
    5alpha-Reductase inhibitors such as finasteride are prohibited in sports according to the World Anti-Doping Agency...
  13. Fenter T, Runken M, Black L, Eaddy M. Finasteride versus dutasteride: a real-world economic evaluation. Am J Manag Care. 2007;13 Suppl 1:S23-8 pubmed
    The objective of this study was to assess the economic differences between dutasteride and finasteride patients within the first year of initiating treatment...
  14. Lee J, Lee S, Kim S, Kim C, Lee H, Kim C, et al. Change in International Prostate Symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea. Urology. 2011;77:171-6 pubmed publisher
    ..change of International Prostate Symptom Score (IPSS) storage subscore after combination therapy (?-blocker and finasteride) in patients with lower urinary tract symptoms (LUTS) consistent with moderate-to-severe benign prostatic ..
  15. Urbatzka R, Watermann B, Lutz I, Kloas W. Exposure of Xenopus laevis tadpoles to finasteride, an inhibitor of 5-alpha reductase activity, impairs spermatogenesis and alters hypophyseal feedback mechanisms. J Mol Endocrinol. 2009;43:209-19 pubmed publisher
    ..the involvement of 5-alpha reductases in maturation of gametes in amphibians, Xenopus laevis was exposed to finasteride (FIN), a known inhibitor of 5-alpha reductase enzyme activity...
  16. Banez L, Blake G, McLeod D, Crawford E, Moul J. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU Int. 2009;104:310-4 pubmed publisher
    To compare the efficacy and tolerability of peripheral androgen blockade using combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for treating biochemical relapse after the definitive management of prostate ..
  17. Nickel J, Gilling P, Tammela T, Morrill B, Wilson T, Rittmaster R. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011;108:388-94 pubmed publisher
    To assess the efficacy and safety of dutasteride compared with finasteride in treating men with symptomatic benign prostatic hyperplasia (BPH) for 12 months...
  18. Peng D, Huang K, Liu Y, Liu S. Preparation of novel polymeric microspheres for controlled release of finasteride. Int J Pharm. 2007;342:82-6 pubmed
    ..of the novel polycarbonate, poly(propylene carbonate maleate) (PPCM) to encapsulate and control the release of finasteride, via microspheres, was investigated...
  19. Kumar R, Singh B, Bakshi G, Katare O. Development of liposomal systems of finasteride for topical applications: design, characterization, and in vitro evaluation. Pharm Dev Technol. 2007;12:591-601 pubmed
    b>Finasteride (FNS) is a "drug of choice" for benign prostate hypertrophy and prostate cancer...
  20. Frink M, Hsieh Y, Hu S, Hsieh C, Pape H, Choudhry M, et al. Mechanism of salutary effects of finasteride on post-traumatic immune/inflammatory response: upregulation of estradiol synthesis. Ann Surg. 2007;246:836-43 pubmed
    The aim of this study was to evaluate whether pretreatment with finasteride, a 5alpha-reductase inhibitor, improves immune functions after trauma-hemorrhage...
  21. Cho Y, Takahashi S, Asamoto M, Suzuki S, Tang M, Shirai T. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model. Prostate Cancer Prostatic Dis. 2007;10:378-83 pubmed
    ..b>Finasteride and flutamide were administered to 10-week-old TG rats five times a week for 2, 5 and 7 weeks...
  22. Hamilton R, Kahwati L, Kinsinger L. Knowledge and use of finasteride for the prevention of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:2164-71 pubmed publisher
    ..The Prostate Cancer Prevention Trial (PCPT) showed that finasteride was effective in reducing the incidence of prostate cancer...
  23. Thompson I, Pauler Ankerst D, Chi C, Goodman P, Tangen C, Lippman S, et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007;25:3076-81 pubmed
    Using data from men in the finasteride group of the Prostate Cancer Prevention Trial (PCPT), we evaluated the impact of prostate-specific antigen (PSA) and other risk factors on the risk of prostate cancer...
  24. Kaufman K, Rotonda J, Shah A, Meehan A. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol. 2008;18:400-6 pubmed publisher
    ..Our objectives were to examine whether finasteride 1 mg treatment decreases the likelihood of developing further visible hair loss in men with AGA...
  25. Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?. J Sex Med. 2007;4:1708-12 pubmed
    ..as erectile dysfunction (ED), loss of libido, and ejaculation disorders have been consistent side effects of finasteride in a maximum percentage of 15% after 1 year of therapy...
  26. Issa M, Runken M, Grogg A, Shah M. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. Am J Manag Care. 2007;13 Suppl 1:S10-6 pubmed
    ..5-alpha reductase inhibitor (5ARI) therapy and to compare the 2 currently available 5ARIs, dutasteride and finasteride, in a real-world, managed care setting...
  27. Byrns M, Mindnich R, Duan L, Penning T. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5?-reductase inhibitor finasteride. J Steroid Biochem Mol Biol. 2012;130:7-15 pubmed publisher
    ..When 5?-reductase was inhibited by finasteride, the production of testosterone-17?-glucuronide was further elevated in LNCaP-AKR1C3 cells...
  28. Wang Y, Gupta S, Hua V, Ramos Garcia R, Shevrin D, Jovanovic B, et al. Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model. Prostate. 2010;70:147-54 pubmed publisher
    We have previously reported that finasteride administration in intermittent androgen deprivation therapy (IADT) can improve survival of nude mice bearing LNCaP xenograft tumors when the duration of off-cycle in IADT was fixed...
  29. Mukai Y, Higashi T, Nagura Y, Shimada K. Studies on neurosteroids XXV. Influence of a 5alpha-reductase inhibitor, finasteride, on rat brain neurosteroid levels and metabolism. Biol Pharm Bull. 2008;31:1646-50 pubmed
    In this study, we examined the influence of finasteride (FIN), a 5alpha-reductase inhibitor, on the brain levels and metabolism of neurosteroids [allopregnanolone (AP), 3alpha-dihydroprogesterone (3alpha-DHP), progesterone (PROG), ..
  30. Cohen Y, Liu K, Heyden N, Carides A, Anderson K, Daifotis A, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1366-74 pubmed
    ..8% reduction in the 7-year prevalence of prostate cancer among patients treated with finasteride (5 mg daily) compared with that among patients treated with placebo; however, a 25...
  31. Rachid Filho D, Cavalcanti A, Favorito L, Costa W, Sampaio F. Treatment of recurrent priapism in sickle cell anemia with finasteride: a new approach. Urology. 2009;74:1054-7 pubmed publisher
    To determine whether the use of finasteride controls recurrent priapism in patients with sickle cell anemia. Thirty-five patients with recurrent priapism because of sickle cell disease received finasteride during 120 days...
  32. Murtola T, Tammela T, Määttänen L, Hakama M, Auvinen A. Prostate cancer risk among users of finasteride and alpha-blockers - a population based case-control study. Eur J Cancer. 2007;43:775-81 pubmed
    b>Finasteride has been reported to reduce prostate cancer risk in asymptomatic men. However, in clinical practice finasteride and alpha-blockers are used to treat benign prostatic hyperplasia (BPH)...
  33. Liang Y, Ketchum N, Louden C, Jimenez Rios M, Thompson I, Camarena Reynoso H. The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study. Urol Int. 2012;89:9-16 pubmed publisher
    To perform the first validation study of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator (finPCPTRC) in a contemporary referral population in Mexico...
  34. Park D, Shim J. Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation. Urol Int. 2008;81:441-6 pubmed publisher
    To evaluate the influence of doxazosin and finasteride on histologic findings in benign prostatic hyperplasia accompanied by prostatitis, and to examine the factors related with prostate carcinogenesis...
  35. Othman A, Evans J, Evans I, Harris R, Hodgkinson P. Structural study of polymorphs and solvates of finasteride. J Pharm Sci. 2007;96:1380-97 pubmed
    NMR and XRD data are reported for several new forms of finasteride, including the results of complete structure determinations for three solvates...
  36. Irwig M, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8:1747-53 pubmed publisher
    b>Finasteride has been associated with reversible adverse sexual side effects in multiple randomized, controlled trials for the treatment of male pattern hair loss (MPHL)...
  37. Rao Y, Zheng F, Zhang X, Gao J, Liang W. In vitro percutaneous permeation and skin accumulation of finasteride using vesicular ethosomal carriers. AAPS PharmSciTech. 2008;9:860-5 pubmed publisher
    In order to develop a novel transdermal drug delivery system that facilitates the skin permeation of finasteride encapsulated in novel lipid-based vesicular carriers (ethosomes)finasteride ethosomes were constructed and the morphological ..
  38. Vaughan C, Goldstein F, Tenover J. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. J Androl. 2007;28:875-82 pubmed
    ..replacement in older men with low T levels would improve aspects of cognitive function and that the addition of finasteride would not affect the T-induced cognitive improvements...
  39. Duarte Guterman P, Langlois V, Hodgkinson K, Pauli B, Cooke G, Wade M, et al. The aromatase inhibitor fadrozole and the 5-reductase inhibitor finasteride affect gonadal differentiation and gene expression in the frog Silurana tropicalis. Sex Dev. 2009;3:333-41 pubmed publisher
    ..We investigated the effects of inhibition of cyp19 by fadrozole (FAD), and srd5alpha and srd5beta by finasteride (FIN) during anuran larval development...
  40. Kaplan S, Roehrborn C, Meehan A, Liu K, Carides A, Binkowitz B, et al. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology. 2009;73:935-9 pubmed publisher
    To determine the effect of finasteride relative to placebo on prostate cancer (PCa) risk at each individual Gleason score in the Prostate Cancer Prevention Trial using a post hoc generalization of a prespecified, exploratory, biopsy ..
  41. Memis A, Ozden C, Ozdal O, Guzel O, Han O, Seckin S. Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia. Urol Int. 2008;80:177-80 pubmed publisher
    In the present study we evaluated the effect of short-term finasteride treatment on microvessel density (MVD) which is an indicator of prostatic angiogenesis in patients with hematuria secondary to benign prostatic hyperplasia (BPH)...
  42. Alvarez Lueje A, Brain Isasi S, Nuñez Vergara L, Squella J. Voltammetric reduction of finasteride at mercury electrode and its determination in tablets. Talanta. 2008;75:691-6 pubmed publisher
    b>Finasteride in hydroalcoholic solutions (ethanol/Britton-Robinson buffer, 30/70) exhibits cathodic response in a wide range of pH (-0.5 to 12) using differential pulse (DPP) and test polarography (TP)...
  43. Stanczyk F, Azen C, Pike M. Effect of finasteride on serum levels of androstenedione, testosterone and their 5?-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013;138:10-6 pubmed publisher
    Studies show that treatment of men with 5?-reductase inhibitors such as finasteride is effective for the primary prevention of prostate cancer...
  44. Bauman T, Sehgal P, Johnson K, Pier T, Bruskewitz R, Ricke W, et al. Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues. Prostate. 2014;74:923-32 pubmed publisher
    ..b>Finasteride is a selective inhibitor of 5?-reductase 2, one isozyme of 5?-reductase found in abundance in the human ..
  45. Suzuki R, Satoh H, Ohtani H, Hori S, Sawada Y. Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics. Drug Metab Pharmacokinet. 2010;25:208-13 pubmed
    b>Finasteride, a steroid 5alpha-reductase (5alphaR) inhibitor, is used to treat benign prostatic hyperplasia and androgenetic alopecia...
  46. Neuhouser M, Till C, Kristal A, Goodman P, Hoque A, Platz E, et al. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2010;3:279-89 pubmed publisher
    ..study within the Prostate Cancer Prevention Trial (PCPT), a randomized, placebo-controlled trial testing finasteride versus placebo for primary prevention of prostate cancer...
  47. Elliott C, Shinghal R, Presti J. The influence of prostate volume on prostate-specific antigen performance: implications for the prostate cancer prevention trial outcomes. Clin Cancer Res. 2009;15:4694-9 pubmed publisher
    ..25% reduction in the biopsy prevalence of cancer compared with placebo in the Prostate Cancer Prevention Trial, finasteride was associated with a higher prevalence of high-grade disease...
  48. Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila). 2008;1:182-6 pubmed publisher
    ..showed a decreased prostate cancer rate but an increased rate of high Gleason grade disease on biopsy for finasteride versus placebo...
  49. Camacho F, García Hernández M, Fernández Crehuet J. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old. Br J Dermatol. 2008;158:1121-4 pubmed publisher
    b>Finasteride is a 5alpha-reductase inhibitor that has proved to be an effective treatment for men with androgenetic alopecia...
  50. Gorin Meyer R, Wiren K, Tanchuck M, Long S, Yoneyama N, Finn D. Sex differences in the effect of finasteride on acute ethanol withdrawal severity in C57BL/6J and DBA/2J mice. Neuroscience. 2007;146:1302-15 pubmed
    ..The 5alpha-reductase inhibitor finasteride can block the formation of ALLO and other GABAergic neurosteroids and also reduce certain effects of EtOH...
  51. Das K, Lorena P, Ng L, Lim D, Shen L, Siow W, et al. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocr Relat Cancer. 2010;17:757-70 pubmed publisher
    ..PC was also examined in prostate cell lines, LNCaP, PC3, and RWPE-1, by treating them with the SRD5A inhibitors finasteride and dutasteride, followed by western blot, quantitative PCR, and ELISA chip array techniques...
  52. Collodel G, Scapigliati G, Moretti E. Spermatozoa and chronic treatment with finasteride: a TEM and FISH study. Arch Androl. 2007;53:229-33 pubmed
    b>Finasteride is a specific inhibitor of the 5alpha reductase enzyme originally approved for the treatment of benign prostatic hypertrophy and also for the treatment of androgenetic alopecia (AGA) in men at a dose of 1 mg/day...
  53. Thompson I, Lucia M, Redman M, Darke A, La Rosa F, Parnes H, et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol. 2007;178:107-9; discussion 110 pubmed
    ..In the Prostate Cancer Prevention Trial we evaluated the impact of finasteride on the risk of a needle biopsy diagnosis of high grade prostatic intraepithelial neoplasia.